TO THE EDITOR Regarding our publication in the September issue of this journal (Vergilis et al., 2005) , our purpose was to find a serological marker that was present in early-as well as late-stage melanoma. Our study showed that the marker CYT-MAA was detectable in the serum of 61% of patients and its presence correlated with a poorer prognosis, regardless of disease stage. At the same time, we evaluated the marker HMW-MAA (also known as melanoma-associated chondroitin sulfate proteoglycan) in the serum of the same patients. Ulmer et al. (2004) suggest (see letter in this issue) that the presence of the HMW-MAA may be related to the presence of circulating melanoma cells that express that antigen. This is certainly possible, as we have previously shown that circulating melanoma cells are present in patients with resected melanoma (Bystryn et al., 2000) , and that their presence is related to treatment and to the clinical outcome of the patients (Reynolds et al., 2003) . On the other hand, HMW-MAA is shed by melanoma cells, so that the presence of this antigen in the circulation could also reflect residual tumor burden. The differences in the expression of HMW-MAA and the stage of disease between our study and that of Ulmer et al. (2004) may, among other causes, be owing to the differences in the type of patients that were studied, their prior treatment, and the assays themselves.
It is clear from our study (Vergilis et al., 2005) that assays can be developed to measure serological markers in patients who have melanoma that has not yet progressed to stage IV disease. Which method and marker alone or combination will prove to be the most sensitive remains to be determined. Thus, studying combinations of markers, as suggested by Ulmer et al., is certainly a good idea. However, we no longer study circulating melanoma cells as their measurement is more difficult than measuring melanoma antigens and requires special handling of blood, which is difficult to do in clinical practice. 
